AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Properties: Suxibuzone belongs to the class of NSAIDs, which work by inhibiting the enzyme cyclooxygenase (COX), thereby reducing the production of prostaglandins, which are substances involved in inflammation, pain, and fever. By decreasing inflammation, suxibuzone can alleviate pain and swelling associated with various conditions in horses.
Equine Use: Suxibuzone is primarily indicated for the treatment of musculoskeletal disorders and inflammatory conditions in horses, including osteoarthritis, laminitis, and soft tissue injuries. It is commonly prescribed by veterinarians to manage pain and inflammation in horses involved in athletic activities or suffering from chronic joint problems.
Analgesic Effects: In addition to its anti-inflammatory properties, suxibuzone also possesses analgesic (pain-relieving) effects, which can help alleviate discomfort and improve the mobility and quality of life of affected horses.
Oral Administration: Suxibuzone is typically administered orally, either as tablets, granules, or paste formulations. The dosage and duration of treatment depend on the specific condition being treated, the severity of symptoms, and the individual horse's response to therapy.
Side Effects: Like other NSAIDs, suxibuzone may cause adverse effects in horses, including gastrointestinal ulceration, renal toxicity, and hepatotoxicity. Long-term use or administration at high doses may increase the risk of these adverse effects. It is essential for horse owners and caretakers to closely monitor for signs of gastrointestinal upset (e.g., colic, diarrhea), changes in appetite, or other unusual symptoms during suxibuzone therapy.
Veterinary Guidance: Suxibuzone should only be used in horses under the supervision and guidance of a veterinarian. Before initiating treatment, the veterinarian will perform a thorough examination to assess the horse's condition and determine the most appropriate treatment plan, which may include suxibuzone alone or in combination with other therapies.
Alternatives: In some cases, alternative medications or therapies may be considered for the management of pain and inflammation in horses, particularly if there are concerns about the potential side effects of NSAIDs like suxibuzone. These alternatives may include other NSAIDs, corticosteroids, joint supplements, physical therapy, and rest.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 1.4 | 0.3 | 3.67 |
| Allergic Rhinitis (Hay Fever) | 1.1 | 0.2 | 4.5 |
| Allergies | 1.1 | 1.6 | -0.45 |
| Allergy to milk products | 1.3 | 0.4 | 2.25 |
| Alzheimer's disease | 1.8 | 1.8 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.5 | 1.6 | 0.56 |
| Ankylosing spondylitis | 1.3 | 1.4 | -0.08 |
| Anorexia Nervosa | 0.9 | -0.9 | |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 0.1 | 1.1 | -10 |
| Atherosclerosis | 0.5 | 0.4 | 0.25 |
| Atrial fibrillation | 1.4 | 0.6 | 1.33 |
| Autism | 3.8 | 3.8 | 0 |
| Barrett esophagus cancer | 0 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 0.9 | 0.7 | 0.29 |
| Brain Trauma | 0.1 | 0.2 | -1 |
| Carcinoma | 1.2 | 0.6 | 1 |
| Celiac Disease | 1.1 | 1.2 | -0.09 |
| Cerebral Palsy | 0.7 | 0.6 | 0.17 |
| Chronic Fatigue Syndrome | 3.1 | 1.4 | 1.21 |
| Chronic Kidney Disease | 1.2 | 0.6 | 1 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 0.6 | 1.17 |
| Chronic Urticaria (Hives) | 1.3 | 1 | 0.3 |
| Coagulation / Micro clot triggering bacteria | 1.2 | 0.6 | 1 |
| Colorectal Cancer | 3 | 0.1 | 29 |
| Constipation | 0.7 | 0.7 | |
| Coronary artery disease | 1 | 0.3 | 2.33 |
| COVID-19 | 3.5 | 5.2 | -0.49 |
| Crohn's Disease | 3.6 | 2.4 | 0.5 |
| cystic fibrosis | 0.9 | 0.2 | 3.5 |
| deep vein thrombosis | 0.9 | 0.6 | 0.5 |
| Depression | 3.5 | 3.3 | 0.06 |
| Dermatomyositis | 0.3 | 0.1 | 2 |
| Eczema | 0.9 | 1.7 | -0.89 |
| Endometriosis | 1.7 | 0.6 | 1.83 |
| Eosinophilic Esophagitis | 0 | 0 | |
| Epilepsy | 1.6 | 1.1 | 0.45 |
| Fibromyalgia | 0.1 | 1.1 | -10 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 1.1 | 1.64 |
| gallstone disease (gsd) | 0.8 | 0.1 | 7 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 1.6 | 0.6 | 1.67 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0.2 | 0.2 | |
| Halitosis | 0.2 | 0.3 | -0.5 |
| Hashimoto's thyroiditis | 0.6 | 0.2 | 2 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.2 | 5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.6 | -5 |
| hyperglycemia | 0.3 | 1.1 | -2.67 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.4 | |
| hypertension (High Blood Pressure | 1.5 | 1.6 | -0.07 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 2 | -2 | |
| Inflammatory Bowel Disease | 3.4 | 3.3 | 0.03 |
| Insomnia | 0.4 | 0.4 | 0 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 2.2 | 1.9 | 0.16 |
| Liver Cirrhosis | 1.9 | 1.5 | 0.27 |
| Long COVID | 3.1 | 2.6 | 0.19 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| ME/CFS with IBS | 0.9 | 0.8 | 0.13 |
| ME/CFS without IBS | 1 | 0.2 | 4 |
| Menopause | 0.7 | 0.7 | |
| Metabolic Syndrome | 3.5 | 3 | 0.17 |
| Mood Disorders | 4.9 | 3.3 | 0.48 |
| multiple chemical sensitivity [MCS] | 1.5 | 1.5 | |
| Multiple Sclerosis | 2.7 | 1.9 | 0.42 |
| Multiple system atrophy (MSA) | 1 | 0.4 | 1.5 |
| Neuropathy (all types) | 0.6 | 0.3 | 1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.9 | -2.17 |
| NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
| Obesity | 2.5 | 3 | -0.2 |
| obsessive-compulsive disorder | 3.6 | 1.8 | 1 |
| Osteoarthritis | 1.4 | 0.4 | 2.5 |
| Osteoporosis | 0.9 | 0.8 | 0.13 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 2.1 | 2 | 0.05 |
| Polycystic ovary syndrome | 0.9 | 1.2 | -0.33 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Psoriasis | 2.1 | 1.1 | 0.91 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.7 | 1.1 | 1.45 |
| Rosacea | 0.5 | 0.1 | 4 |
| Schizophrenia | 2.3 | 0.8 | 1.87 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 0.6 | 0.6 | 0 |
| Sleep Apnea | 0.8 | 0.5 | 0.6 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.1 | 0.18 |
| Systemic Lupus Erythematosus | 2.1 | 0.7 | 2 |
| Tic Disorder | 0.4 | 0.1 | 3 |
| Tourette syndrome | 0.3 | 0.2 | 0.5 |
| Type 1 Diabetes | 2.2 | 0.7 | 2.14 |
| Type 2 Diabetes | 3.5 | 3.5 | 0 |
| Ulcerative colitis | 1.6 | 2.3 | -0.44 |
| Unhealthy Ageing | 2.5 | 0.7 | 2.57 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.